Boston Scientific (BSX) drew fresh attention after Blackstone Life Sciences agreed to provide up to US$455 million to co fund development of the VITALYST heart pump for cardiogenic shock patients.
For investors watching Boston Scientific, the story is a mix of sharp swings and conflicting signals. The share price fell 4.23% over the last day but is still up 2.81% over 30 days, while the year to date share price return is down 54.86% and the 1 year total shareholder return is down 57.26%, pointing to pressure that contrasts with recent product news, recalls and the fresh Blackstone funding commitment.
Scan how Boston Scientific compares to other medical device plays facing similar product risks and clinical catalysts by checking the hand picked 29 resilient stocks with low risk scores in this space.
The share price slide leaves Boston Scientific looking very different to a year ago. Does that reset create an opening now, or argue for waiting until the recalls, earnings resets and new heart pump funding are fully absorbed in the valuation work that follows?
Most Popular Narrative: 26% Undervalued
The most widely followed valuation story for Boston Scientific puts fair value at $57.82, well above the last close of $42.75, which frames the recent selloff as more than just sentiment. That view leans heavily on how the product pipeline and cost savings program reshape earnings power over the next few years.
Investment in proprietary, higher margin technologies and acquired platforms is evolving through the planned SEISMIQ coronary IVL launch, the expected completion of the Penumbra acquisition, and the MiRus option on the SIEGEL TAVR valve. Together these initiatives expand Boston Scientific’s exposure to large interventional cardiology and neurovascular markets and are aimed at supporting long term revenue growth and gross margin mix.
See why 89 investors see Boston Scientific as 26% undervalued.
Result: Fair Value of $57.82 (UNDERVALUED)
Still, if the cyberattack hits earnings harder than expected or if recalls weigh on high margin cardiovascular lines, the Boston Scientific undervaluation story could crack.
Find out about the key risks to this Boston Scientific narrative.
Next Steps
Given that sentiment around Boston Scientific is split between concern and cautious optimism, it helps to look at the data yourself and move quickly to your own judgment. To weigh both sides in one place, start with the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Boston Scientific?
Do not stop with Boston Scientific. Use the screeners below to pressure test your next move and avoid leaving better aligned opportunities on the table.
- Target stability first and sift through a list of solid balance sheet and fundamentals (24 results) to find businesses where financial foundations do more of the heavy lifting.
- Hunt for value and scan a 39 high quality undervalued stocks that filters for quality companies trading at prices that may not fully reflect their fundamentals.
- Get ahead of the crowd and comb through 19 high quality undiscovered gems that pair strong numbers with lower profile coverage before attention potentially widens.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com